Review of Ranibizumab Trials for Neovascular Age-Related Macular Degeneration

Author： Patel Ravi D.   Momi Rominder S.   Hariprasad Seenu M.  

Publisher： Informa Healthcare

ISSN： 0882-0538

Source： Seminars in Ophthalmology, Vol.26, Iss.6, 2011-11, pp. : 372-379

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 231, Iss. 2, 2013-12 ,pp. : 80-85

Karger

Access to resources Recommend Favorite

Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 227, Iss. 1, 2012-04 ,pp. : 11-20

Karger

Access to resources Recommend Favorite

Characteristics and Predictors of Early and Delayed Responders to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials

By  

Ophthalmologica, Vol. 236, Iss. 4, 2016-10 ,pp. : 193-200

Karger

Access to resources Recommend Favorite

Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 370-375

Karger

Access to resources Recommend Favorite

Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial

By  

Ophthalmologica, Vol. 234, Iss. 1, 2015-06 ,pp. : 40-54

Karger

Access to resources Recommend Favorite